Literature DB >> 18308386

PU.1 and CEBPA expression in acute myeloid leukemia.

Francesco D'Alò1, Annalisa Di Ruscio, Francesco Guidi, Emiliano Fabiani, Mariangela Greco, Carlo Rumi, Stefan Hohaus, Maria Teresa Voso, Giuseppe Leone.   

Abstract

Alterations of the transcription factors CCAAT/enhancer binding protein alpha (CEBPA) and PU.1 have been described in acute myeloid leukemia (AML). We studied CEBPA and PU.1 mRNA levels by real-time RT-PCR in 109 primary AML samples, compared with normal bone marrow and peripheral blood cells. Low PU.1 levels were observed in monoblastic leukemias, while low CEBPA levels were associated with leukopenia at diagnosis and lack of expression of differentiation antigens CD33 and CD11c. We conclude that down-regulation of CEBPA and PU.1 is not a general feature of primary AML, but appears to be restricted to distinct AML subtypes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18308386     DOI: 10.1016/j.leukres.2008.01.007

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  7 in total

1.  Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome.

Authors:  Michaela Dostalova Merkerova; Zdenek Krejcik; Hana Votavova; Monika Belickova; Alzbeta Vasikova; Jaroslav Cermak
Journal:  Eur J Hum Genet       Date:  2010-12-08       Impact factor: 4.246

2.  CEBPA-mediated upregulation of the lncRNA PLIN2 promotes the development of chronic myelogenous leukemia via the GSK3 and Wnt/β-catenin signaling pathways.

Authors:  Chengming Sun; Shuping Luan; Guili Zhang; Na Wang; Huiyuan Shao; Caifu Luan
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

3.  The Clinicopathological Impact of Granulocyte-Macrophage Colony-Stimulating Factor Gene Expression and Different Molecular Prognostic Biomarkers in Egyptian Acute Myeloid Leukemia Patients.

Authors:  Bassant Nagdy; Hebatallah A Kassem; Abdel-Rahman B Abdel-Ghaffar; Dina M Seoudi; Neemat M Kassem
Journal:  Asian Pac J Cancer Prev       Date:  2020-07-01

4.  Investigation of CEBPA and CEBPA-AS Genes Expression in Acute Myeloid Leukemia.

Authors:  Milad Gholami; Sahar Bayat; Saba Manoochehrabadi; Hossein Pashaiefar; Mir Davood Omrani; Hasan Jalaeikhoo; Vahid Reza Yassaee; Mohammad Reza Ebrahimpour; Farkhondeh Behjati; Reza Mirfakhraie
Journal:  Rep Biochem Mol Biol       Date:  2019-01

5.  Induced myelomonocytic differentiation in leukemia cells is accompanied by noncanonical transcription factor expression.

Authors:  Holly A Jensen; Harmony B Yourish; Rodica P Bunaciu; Jeffrey D Varner; Andrew Yen
Journal:  FEBS Open Bio       Date:  2015-09-28       Impact factor: 2.693

6.  Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes.

Authors:  Isabella Faraoni; Maria Irno Consalvo; Francesca Aloisio; Emiliano Fabiani; Manuela Giansanti; Francesca Di Cristino; Giulia Falconi; Lucio Tentori; Ambra Di Veroli; Paola Curzi; Luca Maurillo; Pasquale Niscola; Francesco Lo-Coco; Grazia Graziani; Maria Teresa Voso
Journal:  Cancers (Basel)       Date:  2019-09-16       Impact factor: 6.639

7.  Association between the CEBPA and c-MYC genes expression levels and acute myeloid leukemia pathogenesis and development.

Authors:  Adrian Krygier; Dagmara Szmajda-Krygier; Aleksandra Sałagacka-Kubiak; Krzysztof Jamroziak; Marta Żebrowska-Nawrocka; Ewa Balcerczak
Journal:  Med Oncol       Date:  2020-11-10       Impact factor: 3.064

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.